In vivo intervention with recombinant human interleukin-1 receptor antagonist (rhIL-1Ra) can reduce the secretion of TNF-alpha and interleukin-17 (IL-17) and the infiltration of inflammatory cells in the liver thereby inhibiting ConA-induced hepatitis [34]. This evidence concerns the gene IL17A and Hepatitis.